PriceTargets.com logo

Adicet Bio - ACET Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 675.51%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.97 As of 11/20/2024 01:00 AM ET
▼ -0.06 (-5.84%)

This chart shows the closing price for ACET by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adicet Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACET and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACET

Analyst Price Target is $7.50
▲ +675.51% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adicet Bio in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 675.51% upside from the last price of $0.97.

This chart shows the closing price for ACET for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Adicet Bio. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2024HC WainwrightReiterated RatingNeutral
11/7/2024WedbushReiterated RatingOutperform$5.00
10/16/2024HC WainwrightReiterated RatingNeutral
9/30/2024HC WainwrightReiterated RatingNeutral
9/30/2024GuggenheimInitiated CoverageHold ➝ Buy$7.00
9/20/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
9/19/2024HC WainwrightReiterated RatingNeutral
9/11/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$19.00 ➝ $8.00
9/11/2024HC WainwrightDowngradeBuy ➝ Neutral
9/10/2024WedbushReiterated RatingOutperform$5.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/14/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
8/13/2024WedbushReiterated RatingOutperform$5.00
7/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2024WedbushReiterated RatingOutperform$5.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
4/23/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
3/20/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00
3/20/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$19.00
2/5/2024WedbushReiterated RatingOutperform$15.00
2/2/2024HC WainwrightLower TargetBuy ➝ Buy$26.00 ➝ $10.00
1/4/2024WedbushReiterated RatingOutperform$5.00
11/9/2023WedbushLower TargetOutperform ➝ Outperform$17.00 ➝ $5.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$27.00
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$38.00 ➝ $26.00
8/10/2023BTIG ResearchLower TargetBuy ➝ Buy$20.00 ➝ $10.00
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$17.00
6/27/2023GuggenheimDowngradeBuy ➝ Neutral
6/27/2023WedbushLower Target$30.00 ➝ $17.00
6/27/2023BTIG ResearchLower Target$34.00 ➝ $20.00
6/27/2023JMP SecuritiesDowngradeOutperform ➝ Market Perform
6/1/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00 ➝ $6.00
3/17/2023JMP SecuritiesReiterated RatingBuy$19.00
3/16/2023HC WainwrightReiterated RatingBuy$38.00
3/16/2023WedbushReiterated RatingOutperform$30.00
12/12/2022HC WainwrightBoost TargetBuy$34.00 ➝ $38.00
11/16/2022WedbushBoost Target$30.00
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$23.00
8/23/2022Truist FinancialLower Target$27.00
6/7/2022JMP SecuritiesReiterated RatingBuy$21.00
3/31/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$28.00
3/17/2022JMP SecuritiesLower TargetMarket Outperform$30.00 ➝ $21.00
3/8/2022Truist FinancialInitiated CoverageBuy$30.00
3/4/2022Jefferies Financial GroupInitiated CoverageBuy$27.00
12/7/2021HC WainwrightReiterated RatingBuy$34.00
12/7/2021JMP SecuritiesReiterated RatingBuy$30.00
12/6/2021GuggenheimBoost TargetBuy ➝ Buy$22.00 ➝ $32.00
11/15/2021JMP SecuritiesReiterated RatingBuy$30.00
8/24/2021JonestradingReiterated RatingBuy$33.00
5/17/2021BTIG ResearchInitiated CoverageBuy$34.00
5/5/2021JonestradingInitiated CoverageBuy$33.00
4/29/2021HC WainwrightInitiated CoverageBuy$27.00
4/29/2021JonestradingInitiated CoverageBuy$33.00
4/23/2021HC WainwrightInitiated CoverageBuy$27.00
4/14/2021GuggenheimInitiated CoverageBuy$22.00
4/8/2021GuggenheimInitiated CoverageBuy$22.00
11/4/2020B. RileyInitiated CoverageBuy$30.00
10/27/2020JMP SecuritiesInitiated CoverageOutperform$30.00
10/16/2020B. RileyReiterated RatingBuy
10/16/2020First AnalysisDowngradeHold
10/15/2020WedbushInitiated CoverageNeutral ➝ Outperform$25.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 3 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Adicet Bio logo
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $0.97
Low: $0.94
High: $1.06

50 Day Range

MA: $1.36
Low: $0.95
High: $1.53

52 Week Range

Now: $0.97
Low: $0.93
High: $3.77

Volume

1,034,579 shs

Average Volume

1,105,490 shs

Market Capitalization

$79.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Adicet Bio?

The following Wall Street research analysts have issued reports on Adicet Bio in the last year: Canaccord Genuity Group Inc., Guggenheim, HC Wainwright, StockNews.com, and Wedbush.
View the latest analyst ratings for ACET.

What is the current price target for Adicet Bio?

0 Wall Street analysts have set twelve-month price targets for Adicet Bio in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 675.5%. HC Wainwright has the highest price target set, predicting ACET will reach $10.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $5.00 for Adicet Bio in the next year.
View the latest price targets for ACET.

What is the current consensus analyst rating for Adicet Bio?

Adicet Bio currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACET.

What other companies compete with Adicet Bio?

Other companies that are similar to Adicet Bio include W.W. Grainger, United Rentals, Fastenal, Watsco and Applied Industrial Technologies. Learn More about companies similar to Adicet Bio.

How do I contact Adicet Bio's investor relations team?

Adicet Bio's physical mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company's listed phone number is (650) 503-9095 and its investor relations email address is [email protected]. The official website for Adicet Bio is www.aceto.com. Learn More about contacing Adicet Bio investor relations.